Nayla Mumneh MD FAAAAI, FACAAI (She/Her)
Executive Medical director US medical affairs at Novartis
Join to View Full Profile
One health plaza125East Hanover, NJ 07936
Dr. Mumneh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nayla Mumneh is an Allergy and Immunology specialist based in East Hanover, NJ. She completed her medical education at the American University of Beirut Faculty of Medicine and further specialized with residency training in Internal Medicine at Steward Carney Hospital and a fellowship in Allergy and Immunology at New York Presbyterian Hospital. She has served as Medical Director at Novartis since 2019 and previously directed the Allergy Treatment Center of New Jersey. Dr. Mumneh has a clinical focus on conditions including contact dermatitis, asthma, hereditary angioedema, eczema, and common variable immunodeficiency. Her research has been published in various journals, and she has participated in several clinical trials. Recognized for her expertise, she has received multiple honors, including being named a Castle Connolly Top Doctor.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Allergy and Immunology, 1997 - 1999
Steward Carney HospitalResidency, Internal Medicine, 1994 - 1997
American University of Beirut Faculty of MedicineClass of 1992
Certifications & Licensure
NJ State Medical License 1999 - 2027
MA State Medical License 1996 - 2011
American Board of Allergy and Immunology Allergy & Immunology
Awards, Honors, & Recognition
- Castle And Connolly Top Doctor Castle and Connolly, 2014-2019
- Top Doctors New York Metro Area 2016 Castle and Connolly, 2016
- New York Metro Area Top Doctor Castle Connolly, 2015
Clinical Trials
- Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema Start of enrollment: 2010 Feb 01
- Patient Registry Study of Berinert® in Normal Clinical Practice Start of enrollment: 2010 Apr 01
Publications & Presentations
PubMed
- 4 citationsAdeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics.Rudolf W van Olden, Christophe Lo Bianco, Keith W Dilly, Marina Savelieva, Siyan Xu
Molecular Therapy. Methods & Clinical Development. 2024-12-12 - 16 citationsOmalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA.Nicola A. Hanania, Spyridon Fortis, Tmirah Haselkorn, Sachin Gupta, Nayla Mumneh
The Journal of Allergy and Clinical Immunology. in Practice. 2021-08-19 - 4 citationsAngioedema with severe acute abdominal pain: Think of hereditary angioedema.Nayla Mumneh, Matthew Tick, Marie L. Borum
Clinics and Research in Hepatology and Gastroenterology. 2021-04-14
Committees
- Board member, Asthma Advisory Board-Genentech 2016 - Present
Research History
- Principal InvestigatorPROSPERO-A Prospective Observational Study to Evaluate Predictors of Clinical Response to Omalizumab2013 - Present
- Principal InvestigatorA Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet in Children With a History of Ragweed-Induced Rhinoconjunctivitis, Merck2015 - 2018
- Principal Investigator-OSMO Trial-GSKGlaxoSmithKline / “A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (the OSMO study)”2016 - 2017
- Principle Investigator-SAHARA Trial-ShireA Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Administration of 2000 U of C1 Esterase Inhibitor [human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents2016 - 2017
- Principal InvestigatorUnderstanding Refractory Chronic Idiopathic Urticaria (CIU) in the US, Novartis2015 - 2015
Professional Memberships
- Fellow
- American College of Allergy Asthma and ImmunologyFellow
Other Languages
- Arabic, French, Spanish
Industry Relationships
- Speaker Bureau, Bausch and LombBepreve2012 - Present
External Links
- Allergy Treatment Center of New Jerseyhttp://www.allergytreatmentcenter.net
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
